Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study-Reference-Cited by-同舟云学术

Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study

Published:2020-08 Issue:8 Volume:52 Page:869-877
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Yamamoto-Furusho Jesus K.,Al Harbi Othman,Armuzzi Alessandro,Chan Webber,Ponce de Leon Enrique,Qian Jiaming,Shapina Marina,Toruner Murat,Tu Chia-Hung,Ye Byong Duk,Guennec Morgane,Sison Cecilia,Demuth Dirk,Fadeeva Olga,Khan Qasim M. Rana

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference24 articles.

1. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics;Kim;Gut Liver,2010

2. Inflammatory Bowel Disease in Saudi Arabia: challenges and Perspectives;Hafiz;EC Microbiol,2019

3. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease;Wei;Intest Res,2017

4. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease;Wei;Intest Res,2017

5. The Mexican consensus on the diagnosis and treatment of ulcerative colitis;Yamamoto-Furusho;Revista de Gastroenterología de México (English Edition),2018

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure;Gut and Liver;2024-06-05

2. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study;Gastroenterología y Hepatología;2024-01

3. Upregulation of TCPTP in Macrophages Is Involved in IL‐35 Mediated Attenuation of Experimental Colitis;Mediators of Inflammation;2024-01

4. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study;Gastroenterología y Hepatología (English Edition);2024-01

5. Suboptimal Outcomes and Retreatment Rate of Patients With Crohn's Disease After Forced Discontinuation of Biologics: A Nationwide Population‐Based Study;Clinical Pharmacology & Therapeutics;2023-08-16